A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

NCT01937455 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
21
Enrollment
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

International AIDS Vaccine Initiative

Collaborators